Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC): Prospective, Single Arm, Multi-center, Post-Market Clinical Follow-up (PMCF) Study

NCT05911633 is registered in ClinicalTrials.gov with Terumo Europe N.V. as lead sponsor.

NCT NCT05911633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05911633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC): Prospective, Single Arm, Multi-center, Post-Market Clinical Follow-up (PMCF) Study
Lead sponsor
Terumo Europe N.V.
Phase
Not applicable
Overall status
Recruiting
Start date
February 27, 2024
Completion date
December 30, 2027
Enrollment
50 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma non-resectable